Towards drugs targeting multiple proteins in a systems biology approach

被引:40
作者
Keskin, O.
Gursoy, A.
Ma, B.
Nussinov, R.
机构
[1] SAIC Frederick Inc, Ctr Canc Res, Nanobiol Program, Basic Res Program,NCI, Frederick, MD 21702 USA
[2] Koc Univ, Ctr Computat Biol & Bioinformat, TR-34450 Istanbul, Turkey
[3] Koc Univ, Coll Engn, TR-34450 Istanbul, Turkey
[4] Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, Sackler Inst Mol Med, IL-69978 Tel Aviv, Israel
关键词
STRUCTURALLY CONSERVED RESIDUES; HOT-SPOTS; SMALL MOLECULES; BINDING-SITES; REVERSE-TRANSCRIPTASE; COMPUTATIONAL METHODS; DISCOVERY; DESIGN; INTERFACES; RECEPTOR;
D O I
10.2174/156802607780906690
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Protein-protein interactions are increasingly becoming drug targets. This is understandable, since they are crucial at all levels of cellular expression and growth. In practice, targeting specific disease-related interactions has proven difficult, with success varying with specific complexes. Here, we take a Systems Biology approach to targeting protein-protein interactions. Below, we first briefly review drug discovery targeted at protein-protein interactions; we classify protein-protein complexes with respect to their types of interactions and their roles in cellular function and as being targets in drug design; we describe the properties of the interfaces as related to drug design, focusing on hot spots and surface cavities; and finally, in particular, we cast the interactions into the cellular network system, highlighting the challenge of partially targeting multiple interactions in the networks as compared to hitting a specific protein-protein interaction target. The challenge we now face is how to pick the targets and how to improve the efficiency of designed partially-specific multi-target drugs that would block parallel pathways in the network.
引用
收藏
页码:943 / 951
页数:9
相关论文
共 58 条
[1]   Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab [J].
Adams, CW ;
Allison, DE ;
Flagella, K ;
Presta, L ;
Clarke, J ;
Dybdal, N ;
McKeever, K ;
Sliwkowski, MX .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (06) :717-727
[2]   Pocketome via comprehensive identification and classification of ligand binding envelopes [J].
An, JH ;
Totrov, M ;
Abagyan, R .
MOLECULAR & CELLULAR PROTEOMICS, 2005, 4 (06) :752-761
[3]   Protein-protein interactions as a target for drugs in proteomics [J].
Archakov, AI ;
Govorun, VM ;
Dubanov, AV ;
Ivanov, YD ;
Veselovsky, AV ;
Lewi, P ;
Janssen, P .
PROTEOMICS, 2003, 3 (04) :380-391
[4]   Protein-protein interactions and cancer: small molecules going in for the kill [J].
Arkin, M .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2005, 9 (03) :317-324
[5]   Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream [J].
Arkin, MR ;
Wells, JA .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (04) :301-317
[6]   Prediction of protein-protein interactions by combining structure and sequence conservation in protein interfaces [J].
Aytuna, AS ;
Gursoy, A ;
Keskin, O .
BIOINFORMATICS, 2005, 21 (12) :2850-2855
[7]   HIV-1 REVERSE-TRANSCRIPTASE - POLYMERIZATION PROPERTIES OF THE P51 HOMODIMER COMPARED TO THE P66/P51 HETERODIMER [J].
BAVAND, MR ;
WAGNER, R ;
RICHMOND, TJ .
BIOCHEMISTRY, 1993, 32 (40) :10543-10552
[8]   Protein surface analysis for function annotation in high-throughput structural genomics pipeline [J].
Binkowski, TA ;
Joachimiak, A ;
Liang, J .
PROTEIN SCIENCE, 2005, 14 (12) :2972-2981
[9]   Anatomy of hot spots in protein interfaces [J].
Bogan, AA ;
Thorn, KS .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 280 (01) :1-9
[10]   Drugs targeting protein-protein interactions [J].
Chene, Patrick .
CHEMMEDCHEM, 2006, 1 (04) :400-411